AI-Driven Drug Repurposing Market to Reach $10.56 Billion by 2035, Growing at 23.4% CAGR
核心洞察
The global AI in drug repurposing market is projected to surge from $1.28 billion in 2025 to $10.56 billion by 2035, reflecting a 23.4% CAGR driven by demand for faster, cost-efficient drug discovery.
Machine learning and deep learning technologies dominate the market, while oncology leads application segments due to high global cancer (搜索) incidence and urgent need for novel therapies.
North America holds the largest market share, supported by advanced healthcare infrastructure and strong adoption of AI technologies among pharmaceutical and biotech firms.
The global market for artificial intelligence in drug repurposing is poised for explosive growth, with revenues expected to climb from approximately $1.28 billion in 2025 to $10.56 billion by 2035, representing a compound annual growth rate of 23.4%, according to a comprehensive market research study published by Healthcare Foresights.
The report, titled "AI in Drug Repurposing Market Size, Trends and Insights," underscores how AI-powered platforms are fundamentally reshaping pharmaceutical R&D by enabling researchers to analyze vast biological and clinical datasets, predict drug candidate success rates, and identify novel therapeutic applications for existing compounds with unprecedented speed and precision.
Market Drivers: Speed, Cost, and Unmet Need
The accelerating adoption of AI in drug repurposing is fueled by the pharmaceutical industry's pressing need to compress drug discovery timelines and reduce development costs. With the growing prevalence of chronic, rare, and infectious diseases, the demand for rapid identification of effective therapies has intensified. AI platforms address this need by systematically mining biomedical data, real-world evidence, and clinical trial information to uncover new indications for already-approved drugs.
"Artificial intelligence now enables the discovery of new applications for already known drugs with greater precision and accuracy than was possible before," the Healthcare Foresights report states, highlighting how machine learning, natural language processing, and knowledge graph technologies are converging to streamline repurposing workflows.
The integration of AI with clinical trial data, biomedical repositories, and real-world data is further empowering decision-making. Favorable regulatory environments and an increasing shift toward personalized medicine are additional tailwinds propelling market expansion.
Technology and Application Segmentation
Machine learning and deep learning algorithms command the largest technology share within the AI drug repurposing market, owing to their robust capability to analyze massive datasets and generate accurate predictive models. Natural language processing is also expected to register significant growth, playing a pivotal role in extracting actionable insights from unstructured biomedical literature and electronic health records.
By therapeutic application, oncology holds the dominant market position, reflecting the high global incidence of cancer (搜索) and the urgent need to accelerate novel therapeutic discovery. The neurology and cardiology segments also maintain substantial shares, driven by rising disease prevalence. The rare and orphan diseases segment is projected to be the fastest-growing application area, benefiting from the cost-efficient development processes enabled by AI and the limited treatment alternatives currently available for these conditions.
Regional Dynamics
North America accounted for the highest market share, supported by superior healthcare infrastructure, strong technology adoption rates, and a dense concentration of pharmaceutical and biotechnology companies. Europe follows with steady growth, fueled by increasing investments and initiatives facilitating AI integration in healthcare.
The Asia-Pacific region is poised for the fastest growth rate, driven by booming healthcare investments, accelerating AI adoption, and the flourishing pharmaceutical sectors of countries including China and India. Latin America and the Middle East & Africa are expected to grow at moderate rates as healthcare infrastructure upgrades and awareness of AI-based solutions expand.
Competitive Landscape and Recent Developments
The competitive landscape features a mix of established AI-driven drug discovery firms and emerging players. Key companies profiled in the report include BostonGene Corporation (搜索), BenevolentAI, Innophore, Delta4.ai, BioXcel Therapeutics Inc. (搜索), BullFrog AI Holdings Inc. (搜索), Graphwise, Owkin Inc (搜索)., Insilico Medicine (搜索), and Healx (搜索).
In a notable recent development, BioXcel Therapeutics Inc. (搜索) announced in January 2024 an increased investment in its AI-driven drug repurposing platform, aiming to enhance machine learning capabilities and clinical data integration to accelerate new therapeutic area discovery and improve drug development efficiency.
Market Outlook
With the market projected to reach $1.51 billion as early as 2026, the trajectory through 2035 reflects sustained investment in AI-driven healthcare solutions, growing collaborations between pharmaceutical and technology companies, and continuous advancements in AI algorithms. The expanding healthcare infrastructure in developing nations is expected to provide additional long-term growth opportunities, cementing AI-enabled drug repurposing as a cornerstone of modern pharmaceutical R&D strategy.